Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRODIGE 115 ULYSSE
2025-522108-26-00Phase 2Authorised
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in metastatic colon cancer (mCRC) comparing Fruzaqla + FOLFOX/FOLFIRI with Bevacizumab + FOLFOX/FOLFIRI (2 arms). Primary endpoint: Disease Control Rate at 4 months. Planned start Oct 2025; status: authorised.
02
Drugs
fruquintinibbevacizumab
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2025-522108-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522108-26-00.